Hims & Halts Launch of Wegovy Copycat Drug

FDA and Novo Nordisk Pressure on Hims

The U.S. Food and Drug Administration (FDA) recently issued a stern warning to companies producing compounded versions of popular GLP-1 drugs, including semaglutide, the active ingredient in Novo Nordisk’s Wegovy. The FDA emphasized the need to safeguard consumers against unapproved drugs that lack thorough clinical testing for safety, efficacy, and quality. This announcement came alongside Novo Nordisk’s legal threats against telehealth company Hims & Hers for introducing a knockoff version of its FDA-approved Wegovy weight-loss pill.

Novo Nordisk, a market leader in GLP-1 weight-loss medications, has been proactive in protecting its intellectual property. The Danish pharmaceutical giant argued that Hims' compounded drug not only bypassed regulatory approvals but also posed risks to patients due to the absence of controlled clinical trials. The FDA’s statement reinforced these concerns, indicating plans to curb the sale of compounded versions of GLP-1 drugs, particularly as supply shortages ease. These developments have spotlighted the regulatory challenges in the booming weight-loss drug market.

Hims' Decision and Market Impact

Amid mounting regulatory and legal pressures, Hims & Hers announced it would cease offering its compounded Wegovy alternative. Initially priced at $49 per month—significantly lower than Novo Nordisk’s $149-per-month version—the knockoff pill was positioned as an affordable option for patients. However, the move to halt sales reflects Hims’ acknowledgment of both FDA scrutiny and the risk of prolonged legal battles with Novo Nordisk.

This decision marks a shift in Hims' strategy, as the telehealth company had sought to capitalize on the high demand for GLP-1 medications. The withdrawal of its knockoff Wegovy pill may limit its ability to compete in the lucrative weight-loss drug market, valued at billions of dollars annually. Meanwhile, Novo Nordisk’s position remains strong, with plans to promote its new oral Wegovy pill through high-profile advertising campaigns, including a Super Bowl commercial. The broader market is also preparing for increased competition, with rival Eli Lilly expecting FDA approval for its oral weight-loss drug in 2024.